What is the price forecast for adalimumab in 2025?

Adalimumab (Adalimumab) is a fully human monoclonal antibody widely used to treat a variety of immune-mediated diseases. Its main function is to reduce the inflammatory response caused by immune system abnormalities by inhibiting tumor necrosis factor (TNF-α). Adalimumab indications cover a variety of inflammatory diseases, including:

Rheumatoid arthritis (RA): used to relieve joint inflammation, reduce pain, and improve the patient's mobility.

Psoriasis: For the treatment of adults with moderate to severe psoriasis.

Active Psoriatic Arthritis (PA): Reduces joint inflammation and improves joint mobility.

Atopic dermatitis (AD): used to treat patients with severe atopic dermatitis and reduce skin symptoms and inflammation.

Ulcerative colitis: Used to relieve symptoms such as diarrhea and bleeding caused by ulcerative colitis.

Crohn's disease (CD): used to treat patients with Crohn's disease and reduce the inflammatory response in the gastrointestinal tract.

Ankylosing spondylitis: Helps relieve inflammation of the spine and joints and improves the patient's motor function.

Adalimumab has been launched in the country and has been included in medical insurance. In the domestic market, the price of adalimumab40mg/0.4ml* is about more than one thousand yuan, and the monthly treatment cost varies according to the patient’s disease type and treatment plan. For patients on long-term treatment, costs can accumulate. Due to its significant therapeutic effect, the cost of adalimumab may become a burden for some patients, but medical insurance coverage can effectively alleviate this problem.

In overseas markets, the price of adalimumab is usually higher. For example, in the United States, The price of 40mg/0.4ml*2 bottles of the original drug Humira is more than one thousand US dollars. The relatively high price reflects its market value as an original drug. With the launch of biosimilar drugs, the price of adalimumab has gradually declined, and patients can choose the appropriate drug based on their doctor's advice.

Reference materials:https://www.drugs.com/adalimumab.html